Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adecatumumab · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Adecatumumab alone |
| 2 | EXPERIMENTAL | FOLFOX 4 followed by Adecatumumab |
| 3 | ACTIVE_COMPARATOR | FOLFOX 4 alone |
| Name | Type | Description |
|---|---|---|
| Adecatumumab | DRUG | Adecatumumab,6-9mg/kg, every 14 days, 24 cycles |
| Adecatumumab and FOLFOX | DRUG | FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles |
| FOLFOX 4 | DRUG | FOLFOX 4, every 14 days, 12 cycles |
Inclusion Criteria: * Histopathologically confirmed complete resection (R0) of liver metastases from colorectal adenocarcinoma * Age ≥18 years * ECOG performance status ≤ 2 * Patient was informed, has read and understood the patient information / informed consent form and has given written informed...
Adecatumumab is an investigational drug being studied for the treatment of liver metastases, specifically in patients with colorectal cancer who have undergone R0 resection of colorectal liver metastases. It is being evaluated in the oncology therapeutic area as a potential therapy for this condition.
Adecatumumab is a small molecule drug. Its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential role in treating liver metastases from colorectal cancer, but the precise mechanism of action is not specified.
Adecatumumab is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with liver metastases from colorectal cancer.
Adecatumumab is in Phase 2 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. A Phase 2 study has been completed to assess its effects in patients with colorectal liver metastases, but it remains in clinical development.
Adecatumumab has been studied in one clinical trial with the identifier NCT00866944. This Phase 2 study, titled 'Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases,' has been completed. The trial enrolled 35 participants in France and Germany and was active-controlled.
Adecatumumab is not known to have any alternative names. It is a distinct investigational drug being developed by Amgen Inc. for the treatment of liver metastases in colorectal cancer patients. No other names or aliases have been associated with this compound in the available information.